close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

122.81 +4.96 (+4.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
65 66 Next >
$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,000 Today
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
 
Via Benzinga
Where Gilead Sciences Stands With Analysts
 
Via Benzinga
(GILD) - Analyzing Gilead Sciences's Short Interest
 
Via Benzinga
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
 
Via Benzinga
How Is The Market Feeling About Gilead Sciences?
 
Via Benzinga
2 High-Yield Dividend Stocks to Buy on the Dip
The market may have been a bit too harsh on these stocks. 
Via The Motley Fool
3 No-Brainer Dividend Stocks to Buy in September
Income investors should really like these biopharma stocks with juicy dividends. 
Via The Motley Fool
Nearing Retirement? These Stocks Will Pay You For Life
These companies are passive income machines. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
GILD Stock Alert: FDA Approves Gilead Sciences’ Veklury Covid-19 Treatment
Gilead Sciences (GILD) stock is on the move Thursday following additional FDA approval for its Veklury Covid-19 treatment. 
Via InvestorPlace
FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences (GILD) Q2 2023 Earnings Call Transcript
GILD earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Will An Earnings Miss Cloud Gilead's Massive Cancer Treatment Growth?
Gilead missed earnings expectations Thursday, though reported strong sales growth for cancer drugs. 
Via Investor's Business Daily
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus... 
Via Benzinga
How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30%
Roche provided an update from its study in lung cancer using an anti-TIGIT drug. 
Via Investor's Business Daily
San Francisco Business Times Names Landis Communications Inc. (Landis) the Top 2022 Bay Area Corporate Philanthropist as a Percentage Of Profits
--News Direct-- 
Via News Direct
Topics LGBTQ
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years. 
Via Talk Markets
FDA Pauses Gilead's Investigational Magrolimab Study In Blood Cancer Patients
FDA has placed a partial clinical hold on Gilead Sciences Inc (NASDAQ: GILD) initiation of new patients in U.S. 
Via Benzinga
5 Safe Stocks Under $40 to Buy Immediately
Investors are turning away from risky bets and putting their money in safe stocks this week. Here are four names under $40 to buy now. 
Via InvestorPlace
Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States
From Gilead Sciences, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia
Truist has raised the price target for Autolus Therapeutics PLC (NASDAQ: AUTL) from $6 to $9  
Via Benzinga
Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation
From Gilead Sciences, Inc.
Via Business Wire
The 3 Best Biotech Stocks to Buy in August
Even as healthcare stocks suffer from post-pandemic fatigue, these three of the best biotech stocks to buy and ride the wave of good news. 
Via InvestorPlace
Hypertrophic Cardiomyopathy Therapeutics Market Projected to Show Strong Growth : Novartis, Gilead Sciences, ADVANZ PHARMA
Stay up-to-date with Hypertrophic Cardiomyopathy Therapeutics Market research offered by AMA. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Gilead Stock Jumps On Strong Q2 Performance Despite Lower Profit Outlook Amid Litigation
Gilead Sciences Inc's (NASDAQ: GILD) Q2 FY23 sales increased 6% Y/Y to $6.60 billion, above the consensus of $6.43 billion, primarily driven by increased sales in HIV and Oncology, partially offset by... 
Via Benzinga
Market Rally Under Pressure As Yields Soar; Amazon, ELF, Caterpillar Are Earnings Winners: Weekly Review
Amazon, ELF and CAT were earnings winners, but there were big losers too. 
Via Investor's Business Daily
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
65 66 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today